For sales

📢Highlights from the Week of May 27 – June 02, 2025 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of May 27 – June 02, 2025 Fresenius Kabi ( EMA, CHMP, Approval, Denosumab ) Fresenius Kabi's denosumab biosimilars received a positive recommendation from the CHMP for osteoporosis and bone conditions, expanding their portfolios in autoimmune and oncology treatments. EC approval is anticipated in Q3 2025 Bio-Thera & Hikma Pharmaceuticals ( FDA, Biosimilar, Approval, Denosumab ) Bio-Thera Solutions and Hikma Pharmaceuticals announced the FDA approval of STARJEMZA (ustekinumab-hmny) Sandoz ( US, Launch, Biosimilar, Denosumab ) Sandoz expands its US biosimilar portfolio with the launch of WYOST and JUBBONTI, the first interchangeable denosumab biosimilars approved by the FDA Samsung Bioepis ( US, FDA, Adalimumab ) The FDA has designated Samsung Bioepis and Organon's HADLIMA as fully interchangeable with HUMIRA, covering all high- and low-concentration formulations and device types All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.